Genentech, Inc.
NEWS
A roundup of last week’s top clinical trial updates and news.
The U.S. FDA’s Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Interim data from Genentech’s first randomized study on a candidate treatment for extensive-stage small-cell lung cancer failed to meet its co-primary endpoint.
The study suggests that artificial sweeteners, which are readily available in coffee shops and used in diet soft drinks, increase the risks of breast cancer and obesity.
A federal judge in Delaware tossed out a lawsuit by Genentech, Inc., a Roche company, accusing Novartis’ Sandoz division of patent infringement.
It was a busy week for clinical trial announcements. Here’s a look.
JOBS
IN THE PRESS